Supernus Pharmaceuticals Inc (SUPN)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	321,031	418,757	454,848	468,008	467,442	489,145	440,870	414,500	382,420	340,324	326,355	288,181	258,697	221,602	190,722	179,160	176,685	183,085	182,916	181,669
Payables	US$ in thousands	—	3,389	4,400	11,544	10,543	16,015	35,518	12,323	9,331	9,125	7,229	5,954	6,147	11,193	5,515	3,124	10,141	3,090	4,081	7,240
Payables turnover		—	123.56	103.37	40.54	44.34	30.54	12.41	33.64	40.98	37.30	45.15	48.40	42.09	19.80	34.58	57.35	17.42	59.25	44.82	25.09

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $321,031K ÷ $—K
= —

Supernus Pharmaceuticals Inc's payables turnover has shown a significant improvement over the past eight quarters, indicating a positive trend in managing its accounts payable. The company's payables turnover ratio has increased steadily from 2.07 in Q2 2022 to 42.66 in Q4 2023, reflecting a more frequent and efficient payment of its obligations to suppliers. This improvement suggests that Supernus Pharmaceuticals is managing its payables effectively and may be benefiting from favorable credit terms or negotiating better terms with its suppliers. Overall, the upward trend in payables turnover is a positive signal of the company's financial health and operational efficiency.